patients with epilepsy N 16 years of age. A subset of patient claims with a valid index date of AED treatment change (new, add, or switch) were used to train the AED prediction model by retrospectively evaluating an index date treatment for subsequent treatment change. Based on the trained model, a model-predicted AED regimen with the lowest likelihood of treatment change was assigned to each patient in the group of test claims, and outcomes were evaluated to test model validity. Results: The model had 72% area under receiver operator characteristic curve, indicating good predictive power. Patients who were given the model-predicted AED regimen had significantly longer survival rates (time until a treatment change event) and lower expected health resource utilization on average than those who received another treatment. The actual prescribed AED regimen at the index date matched the model-predicted AED regimen in only 13% of cases; there were large discrepancies in the frequency of use of certain AEDs/combinations between model-predicted AED regimens and those actually prescribed. Conclusions: Chances of treatment success were improved if patients received the model-predicted treatment. Using the model's prediction system may enable personalized, evidence-based epilepsy care, accelerating the match between patients and their ideal therapy, thereby delivering significantly better health outcomes for patients and providing health-care savings by applying resources more efficiently. Our goal will be to strengthen the predictive power of the model by integrating diverse data sets and potentially moving to prospective data collection.
Introduction
The clinician's ability to identify antiepileptic drug (AED) regimens that provide each patient with epilepsy with the best possible outcomes is a significant challenge. Clinical trials rarely provide the specificity for individual patient-centric decisions. Even existing epilepsy treatment guidelines provide recommendations on key aspects of care such as the treatment of new-onset epilepsy [1] , treatment-resistant epilepsy [2] , and epilepsy in patients with HIV/AIDS [3] , but do not cater specifically to patients who vary, for example, by age, etiology, and socioeconomic status. Clinicians, therefore, often rely on trial and error.
While seizures in approximately 60% of patients respond to their first AED, another 15% spend 2-5 years finding an effective AED regimen; seizures in the remaining 25-30% are treatment-resistant [4, 5] . This indicates a knowledge gap and significant unmet medical need regarding optimal AED choice for balancing symptom control and tolerability for individuals [6] . Indeed, the initial promise of personalized medicine was alluring in the management of epilepsy, but it has been slow to deliver [7, 8] .
With the increasing amount of clinical data and available AEDs, application of computer learning and data analysis may help physicians easily access the most relevant information to make treatment decisions. This approach takes mass quantities of structured and unstructured data from various sources and asks the computer to learn and return a set of structured answers based only on the most relevant data [9] . A clinical decision support (CDS) system for pediatric epilepsy was developed using a computer system to integrate expert opinion Epilepsy & Behavior 56 (2016) [32] [33] [34] [35] [36] [37] Abbreviations: AED, antiepileptic drug; AUC, area under the curve; CDS, clinical decision support; ICD-9, International Classification of Diseases, Ninth Revision; ROC, receiver operator characteristic.
with a configured knowledge base to make treatment recommendations [10, 11] . A collaboration between UCB and IBM has been made to develop a predictive model offering personalized care for people with epilepsy that uses "cognitive computing" to analyze data involving thousands of longitudinal records, similar to a collaboration between IBM and Memorial Sloan Kettering Cancer Center developing a system to diagnose and treat an individual's cancer [9] . For epilepsy, this modeling approach leverages the increasing aggregation and collation of claims data to predict the chances of treatment success, defined by avoidance of hospitalization or treatment change, based on the similarity of the individual patient's characteristics to a larger patient population. Here, we present our initial findings in epilepsy.
Methods

Data source and patients
Medical, pharmacy, and hospital claims data were collected from all major regions of the United States between January 1, 2006 and September 31, 2011 from the IMS Health Surveillance Data Incorporated (SDI) medical claims database. This database was chosen because it broadly reflects the underlying population of patients with epilepsy including census-like geographic coverage, has full representation of third-party and government payers, and does not require continuous eligibility in a health plan, ensuring that varying socioeconomic status and patient movement across plans/payers each year does not impede the ability to track these patients over time. The SDI database provides de-identified patient data in compliance with Health Insurance Portability and Accountability Act regulations, thus making the study exempt from institutional review board review.
The SDI aggregates patient information from multiple provider sources, but might not capture all claims for an individual patient if providers that do not submit data to SDI were used. To control for this, we employed eligibility requirements for continuous reporting from the sources. Specifically, we required at least 80% continuous monthly eligibility (in 1-year windows) in any of the SDI pharmacy, physician, or hospital databases, and quarterly pharmacy eligibility for each patient. The analysis was performed on the longest eligible data period of the patient, requiring a minimum period of 2 years.
To capture data from patients with epilepsy rather than from patients receiving AEDs for other indications, we defined an analysis set of patients N16 years of age in January 2006, with at least one International Classification of Diseases, Ninth Revision (ICD-9) epilepsy diagnosis code (345.xx) or two seizure diagnosis codes (780.3x) at any time, as well as at least one claim for an AED from a pharmacy with 80% stability (existence of monthly pharmacy claims data) over the whole data period. The final inclusion criterion was that an index date (defined below) was identifiable for the patient.
Choice of index date
An index date was defined as the first date on which a treatment change occurred, where: (1) the new AED regimen switched one or more AEDs in the previous regimen or added an AED to the existing regimen (excluding the case of restarting a past treatment, and including the case of moving from no treatment to AED treatment); (2) the patient had an eligible period of ≥ 12 months before and after this date; (3) the patient had ≥ 3 months of pharmacy eligibility prior to this date; and (4) the treatment was unchanged during the 30-day period after the index date (to eliminate rescue medication in favor of chronic treatment).
The AED regimen following the treatment change event at the index date was defined as the index date AED regimen. The 12-month period before the index date was used to extract patient features, while the 12-month period after the index date was used to determine the outcome.
Choice of outcome
Because the primary symptom of epilepsy-seizures-is not captured in claims data, we used treatment change events as a proxy measure of seizure control and patient status. Intuitively, the need for treatment change indicates that the patient's current treatment regimen was suboptimal in terms of efficacy and/or tolerability. In order to be a valid index date, the treatment had to remain unchanged for at least 30 days post-index date. Therefore, an unsuccessful AED regimen was defined as any change other than a dose change (i.e., increase/decrease) or a complete withdrawal of any AED treatment in the subsequent 1-12 months after the change. Furthermore, longer-term stable treatment or a complete withdrawal from an AED therapy was assumed to indicate successful treatment.
Data analysis
The objective of the UCB-IBM collaboration was to retrospectively estimate the effectiveness of different treatment approaches using large observational data sets and use this information to predict successful treatments for individual patients. We used machine-learning methods to create a predictive algorithm estimating the success probability for a given patient and a specific treatment regimen. This algorithm was then used to predict the treatment regimen with the highest success probability for each patient (model-predicted AED regimen). The effects of using the algorithm's predictions were assessed in terms of treatment change rates and utilization of health-care services using an independent patient set.
Disjoint sets of 40,000 patients for training and 10,000 patients for testing were randomly selected from the patients meeting all study inclusion criteria. To increase the reliability of the results, we excluded patients whose index date treatment regimen was relatively rare (i.e., occurred b50 times in the training population).
Building and testing the model
We used the training set to train a predictive model which, given the patient data 12-month pre-index date and the index date AED regimen, predicts the probability of success. The predictive model was based on features extracted from the data, but not costs or health-care utilization features. From each patient's record, roughly 5000 features were extracted, which include patient features (related to the patient and recorded prior to the index date, e.g., demographics, medication history, comorbidities, ICD-9 codes), treatment features (related to the index date AED regimen-the one to be evaluated-e.g., the number and type of distinct drugs at index date), and patient-treatment features (interactions between patient and treatment). Some features were based on expert knowledge or literature (e.g., classification of AED as first or second generation, AED activity in particular seizure types, mechanism of action [12] [13] [14] ). To reduce the number of features and avoid over-fitting the training data, we used a standard feature selection process. First, we removed constant features (mode frequency N 0.99) and features with small standard deviations. Second, we removed features whose correlation to the outcome was not significant (p N 0.05). Finally, we removed features that were highly correlated to another feature (R N 0.6), where the feature removed was the one with lower correlation to the outcome. The selected features were based on the training set only, and when testing, only these selected features were calculated and used. We used the random forest algorithm [15] , a state-of-the-art prediction model that outputs the majority vote of a multitude of decision trees because this algorithm outperformed other prediction algorithms (results not shown).
The performance of the model's predictions was estimated using receiver operator characteristic (ROC) analysis on the test set. This accuracy was compared with the accuracy of a baseline model, which was defined as a logistic regression on the number of treatment changes the patient had experienced in the 12 months prior to the index date.
Predicting the model-predicted AED regimen
For each patient, the model-predicted AED regimen is the AED regimen having the highest success probability. This is determined for each patient by "plugging in" every possible AED regimen into the model, receiving the probability of success for that patient per regimen, and choosing the regimen with the highest success probability. The set of possible AEDs per patient is chosen as follows: denote by T pre the patient's AED regimen right before the index date. The set of possible AEDs is the set of all index date treatment regimens, B, where T pre → B occurred at least 50 times in the training population. The modelpredicted regimen may or may not be the AED regimen actually prescribed at the index date. Kaplan-Meier analysis was used to determine whether significant differences in outcomes exist between cases in which the model-predicted regimen was prescribed at the index date and cases in which a different treatment was given (i.e., other AED regimen).
Analysis of health-care service utilization
The analysis of health-care service utilization was performed in the year after the index date using the test data set. In this analysis, we investigated several types of resource utilization, such as hospitalization days and number of physician visits. For each utilization type, its actual use (U actual ) was estimated directly from the data set (e.g., calculating the average number of hospitalization days per patient in the year after the index date). The expected use if model-predicted AED regimen was always prescribed was computed in the following manner. First, the population of patients in the test data set was divided into those with successful outcomes and those that failed and calculated the average use per subpopulation: U success and U fail . Second, for each patient in the test data set, the expected utilization was estimated for the model-predicted AED regimen as p * U success + (1 − p) * U fail , where p is the success probability for the patient and the model-predicted AED. Finally, the average expected utilization over all persons in the test data (U model ) was computed, and used the difference between U actual and U model as an approximation for the expected decrease in that utilization. The results presented for utilizations showed significant association with the outcome (t-test; false discovery rate [16] , 0.05).
Results
Data from approximately 140,000 individuals matched inclusion criteria regarding epilepsy diagnosis, age, pharmacy stability, and patient eligibility, and had a valid index date. Random samples of 40,000 patients for training and 10,000 patients for testing were selected. With the additional constraint that an AED regimen must occur ≥ 50 times in the training set, the number of patients was reduced to 34,990 in the training set and 8715 in the test set. After requiring that T pre → B occurs at least 50 times in the test population, the number of patients in the test set for whom the model can make predictions was reduced to 8292. There were a total of 52 different index date AED regimens (monotherapies or combinations of AEDs) in the training set satisfying this requirement. Demographics for the training set are shown in Table 1 . Results were stable across training and test sets.
The predictive model used selected features based on their association with the outcome, excluding those that were also highly correlated to other features. The most dominating features were those related to the complexity of the treatment and the history of treatment change (e.g., number of AEDs at index date and pre-index date, number of treatment changes at pre-index date, number of dose increases, number of restarts). The next highly associated class of features was related to the identity and mechanism(s) of action of the index date AED regimen and pre-index date AEDs (e.g., old-or new-generation AEDs, treatments containing clonazepam, GABA-augmenting mechanism). Demographic features included age + age 2 , gender, and payer type. Background conditions, as identified by diagnoses, procedures, or drugs, were also included-mainly evidence of migraines, psychiatric disorders, and metabolic/cardiovascular disorders. Finally, the prescribing physician specialty also was used as input to the model. Fig. 1 depicts features with the highest correlation to the outcome (i.e., correlation to a change from the index drug regimen). Our model exhibited greater predictive power than the baseline logistic regression model ( Fig. 2A) , as demonstrated by the area under the ROC curves (AUC = 0.715 vs AUC = 0.598, respectively). A retrospective analysis of the test set in the model showed that patients who were given the model-predicted AED regimen (AED regimen with the lowest likelihood of treatment change) had longer median survival rates on average (i.e., longer time until a treatment change event) compared with patients receiving another AED regimen (median N 360 days vs median of 239 days, 95% confidence interval 229-252 days, p b 0.001; Fig. 2B ).
We examined whether physician-chosen AED regimens matched with the model-predicted AED regimens (Fig. 3) . The actual prescribed AED regimen at the index date matched the model-predicted AED regimen with the highest likelihood of treatment success in only 13% of cases; there were large discrepancies in the frequency of use of certain AEDs/combinations between model-predicted AED regimens and those actually prescribed.
There were several major resource savings based on the expected use of the model-predicted AED regimens versus that observed in the test population (Table 2) . For all considered utilization types, patients with successful outcomes had lower values on average than patients with seizures that had unsuccessful outcomes with treatment. For example, among the 8292 patients in the analysis, it was expected that there would be 281.5 fewer epilepsy-related hospitalization days on average if the model-recommended AED regimens were given instead of the actually prescribed AEDs. Along with fewer hospitalization days (particularly epilepsy-related), there were also fewer predicted physician visits and a lesser need for medical procedures (particularly epilepsy-related).
Discussion
We describe the pilot study for a predictive model that can identify AED regimens with the lowest likelihood of subsequent treatment change for an individual patient. The 72% area under ROC curve indicates that this approach has predictive power and the time to treatment change and utilization analyses verify its potential benefit. The model features were based on characteristics of the AEDs (e.g., mechanism of action), the regimen (e.g., number of concomitant AEDs), and patient features (e.g., age). This model supports that older/first-generation AEDs are associated with poorer outcomes [17, 18] . For example, another analysis of patients with epilepsy in the SDI database found that patients taking first-generation AEDs experienced epilepsy-related hospitalizations more frequently than those taking newer second-generation AEDs and that prescriptions for second-generation AEDs were more common among neurologists and among physicians practicing near an epilepsy center [18] . The association between second-generation AEDs and better outcomes may reflect the benefits of these AEDs and/or care by more experienced clinicians. Treatment success increased with age in our model, corroborating others' findings [19] [20] [21] [22] , likely reflecting that causes of later-onset epilepsies (e.g., stroke) are more often treatment-responsive or more likely to spontaneously resolve.
The model-predicted AED regimens produced significantly better than expected outcomes for patients-longer time to subsequent treatment modification event and reductions in predicted health-care resource utilization (hospitalizations, AED use, specialist/physician visits, and other procedures). A recent cost analysis compared patients with epilepsy with stable AED regimens with those with unstable epilepsy (AED added to the regimen) and found that patients with uncontrolled epilepsy used more services and incurred higher costs compared with those with stable epilepsy (mean ± standard deviation, stable $13,839 ± $31,355 vs unstable $23,238 ± $42,894) [23] . Our model's recommendation system could reduce treatment changes and save substantial costs while providing more stability and better outcomes to patients. We chose an open data set to capture a representative US population of patients treated by multiple physician types as well geographic and payer diversities [24] . The population demographics differ from that normally seen in epilepsy clinics in that the population is older, potentially over-representing symptomatic epilepsy and under-representing younger cryptogenic cases, which may bias the algorithm's prediction of AEDs. The limitations are partly offset by the power of the large patient population and may also be compensated for because the model includes patient and AED features when making AED regimen predictions. The major limitation is that we could not evaluate seizure freedom, reductions in seizure frequency, or quality of life. However, our assumption is that the treatment change outcome reflects many potential adverse outcomes (e.g., poor efficacy, poor tolerability, adverse effect on a comorbid disorder, nonadherence, problems with drug fulfillment); at the same time, treatment stability represents success (however, it could also be a matter of patient or physician reluctance to adjust treatment). The surrogate outcomes in claims data sets are not ideal for these predictions; for instance, we know only that a prescription was given, refilled or withdrawn, but we do not know whether the medication was prescribed specifically for epilepsy or was taken as recommended, nor do we know the reason for withdrawal. The high rate of gabapentin (21%) and clonazepam (14%) use at the index date while not typically prescribed by epileptologists suggests that the patterns observed reflect the large proportion of the population treated by nonspecialists, and in at least some of these patients, these AEDs may have been prescribed because of comorbid pain, anxiety, or sleep disorders as they were most often given in combination with other AEDs. Indeed, certain comorbid conditions were features used by the model to make its AED predictions. Future studies should evaluate other populations/databases, other therapies (e.g., diet, surgery, neurostimulation), as well as models with more specific outcome measures (e.g., seizure frequency) and perhaps even prospectively collected electronic medical records.
Conclusions
This study was a proof of concept, and a next step would be iterative evaluations in other populations to refine the algorithm. With the large number of monotherapy and AED combination regimens that could be prescribed, it is perhaps not surprising that only 13% of patients received the model-predicted AED regimen, which suggests that many could potentially benefit if this model was available to clinicians as part of a CDS. The algorithm designated one AED regimen as having the least likelihood of subsequent treatment change (model-predicted AED regimen), although several treatments may have had similar success. Future studies may better define broader categories such as "ideal" (i.e., the 13% in our study), "appropriate", and "not recommended". Our model-predicted AED regimens suggest that a CDS system could be developed to provide pertinent information and treatment recommendations personalized for the individual patient profile. This system would augment the clinician's considerations (e.g., contraindications, drug-drug interactions, comorbidities) to improve epilepsy care. No single AED or AED combination will be optimal for all patients with epilepsy. A CDS system could provide options likely to be effective and eliminate diagnostics unlikely to impact care, improving individualized treatment plans and outcomes in epilepsy.
